PF4 and Fc-Modified Antibodies Stabilize NETs in Sepsis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for sepsis and heparin-induced thrombocytopenia (HIT) often involve intense anticoagulation, which carries risks of bleeding and only provides partial protection against thromboembolic events, and there is a need for targeted therapies that do not rely on heparin exposure, as heparin is not always replaceable in clinical settings.
Innovation Solution
Administration of PF4 or Fc-modified antibodies that bind to neutrophil extracellular traps (NETs) to stabilize them, prevent the release of toxic degradation products, and neutralize lipopolysaccharides, thereby reducing cell activation and inflammation, using antibodies like KKO that are modified to reduce binding to Fc receptors and complement activation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If intense anticoagulation is used to treat HIT, then protection against thromboembolic events is improved, but bleeding risk increases
Solution Approach 1:
The patent extracts and targets the specific pathogenic mechanism (PF4-GAG-antibody complexes on platelets and neutrophils) rather than using broad anticoagulation. By administering PF4 or Fc-modified antibodies that bind to these complexes, the treatment specifically addresses thromboembolic risk without the non-specific bleeding risks of intense anticoagulation.
Solution Approach 2:
The patent uses Fc-modified antibodies as intermediaries to bind PF4-GAG complexes. These modified antibodies have reduced Fc receptor binding and complement activation, allowing them to neutralize the pathogenic complexes without triggering the harmful inflammatory and thrombotic responses that would otherwise occur.
2Reliability
If heparin is avoided to prevent HIT, then development of HIT is prevented, but heparin remains irreplaceable in certain clinical settings
Solution Approach 1:
The patent converts the problematic PF4-GAG-antibody complex formation into a therapeutic opportunity. By administering PF4 or Fc-modified antibodies that bind these complexes, the treatment transforms the pathogenic mechanism into a target for specific therapy, allowing heparin use when clinically necessary without triggering HIT.
3Reliability
If NETs are released to trap bacteria, then microbial entrapment is improved, but toxic degradation products are released causing inflammation
Solution Approach 1:
The patent uses Fc-modified antibodies as intermediaries to bind PF4 on NETs, stabilizing them and preventing degradation. This allows NETs to maintain their microbial entrapment function while avoiding the release of toxic degradation products that would otherwise cause inflammation and tissue damage.
Solution Approach 2:
The patent enables continuous stabilization of NETs through binding of Fc-modified antibodies or PF4, maintaining their structural integrity and microbial entrapment capacity over time without the cyclical release of toxic degradation products that occurs with NET turnover.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances microbial entrapment, reduces NET lysis, and improves outcomes in sepsis and HIT by stabilizing NETs and neutralizing harmful substances, potentially offering a safer and more effective treatment than existing methods.
Implementation Method 1
administration of PF4 or Fc-modified antibodies that bind to neutrophil extracellular traps (NETs) to stabilize them
Implementation Method 2
prevent the release of toxic degradation products, and neutralize lipopolysaccharides, thereby reducing cell activation and inflammation
Implementation Method 3
drugs that do so may either act like PF4 and physically compact the NETs protecting them from lysis by DNase I and other enzymes
Implementation Method 4
neutralizing lipopolysaccharides released from bacterial cell walls
Implementation Method 5
The said Fc-modified antibody exhibits reduced binding to FcR and/or complement activation as compared to an unmodified antibody of the same class and isotype
Data Source
AI summary
The present disclosure is directed to the use of PF4 alone or anti-PF4 antibodies alone or the combination thereof to treat sepsis. Neutrophils release their histone-coated DNA termed neutrophil extracellular traps (NETs) during sepsis and related inflammatory disorders. NETs are broken down and release NET degradation products (NDPs) like histone that are toxic and contribute to the morbidity and mortality in sepsis and related inflammatory disorders. The inventors have shown that a native platelet protein, platelet factor 4 (PF4), which is highly positively-charged, compacts NETs that are in turn highly negatively-charged. These compact NETs are resistant to NDP release and breakdown by circulating DNases. PF4 protects against this lysis and NDP release and improves outcome. The inventors also found that an antibody to PF4 that cross-binds PF4 on NETs further protects against lysis and NDP release. Such antibodies, perhaps supplemented with additional PF4, are therapeutic candidates for treatment of sepsis.